Kymera Therapeutics Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader

Reuters

06-02

Kymera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader medicine. The study demonstrated over 90% mean STAT6 degradation in blood at all doses above 1.5 mg and complete STAT6 degradation in both blood and skin at all multiple ascending doses equal to or greater than 50 mg. KT-621 showed a safety profile similar to placebo, with no serious adverse events reported. The trial's results indicate potential for treating IL-4/IL-13-driven allergic diseases. Kymera plans to begin two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-132760), on June 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540767899"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540767899\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540767899?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540767899","market":"us","top_or_hot":-1,"title":"Kymera Therapeutics Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KYMR\">Kymera Therapeutics, Inc.</a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader medicine. The study demonstrated over 90% mean STAT6 degradation in blood at all doses above 1.5 mg and complete STAT6 degradation in both blood and skin at all multiple ascending doses equal to or greater than 50 mg. KT-621 showed a safety profile similar to placebo, with no serious adverse events reported. The trial's results indicate potential for treating IL-4/IL-13-driven allergic diseases. Kymera plans to begin two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-132760), on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kymera Therapeutics Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKymera Therapeutics Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-02 19:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KYMR\">Kymera Therapeutics, Inc.</a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader medicine. The study demonstrated over 90% mean STAT6 degradation in blood at all doses above 1.5 mg and complete STAT6 degradation in both blood and skin at all multiple ascending doses equal to or greater than 50 mg. KT-621 showed a safety profile similar to placebo, with no serious adverse events reported. The trial's results indicate potential for treating IL-4/IL-13-driven allergic diseases. Kymera plans to begin two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-132760), on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL9FtQ3S:1","article_id":"2540767899","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540767899","pubTimestamp":1748862373,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader medicine. The study demonstrated over 90% mean STAT6 degradation in blood at all doses above 1.5 mg and complete STAT6 degradation in both blood and skin at all multiple ascending doses equal to or greater than 50 mg. KT-621 showed a safety profile similar to placebo, with no serious adverse events reported. The trial's results indicate potential for treating IL-4/IL-13-driven allergic diseases. Kymera plans to begin two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal adv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Kymera Therapeutics公布了KT-621的有希望的1期试验结果，KT-621是一种一流的口服STAT6降解剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":0.9},"content_text":"Kymera Therapeutics Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader\n    \n\nKymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader medicine. The study demonstrated over 90% mean STAT6 degradation in blood at all doses above 1.5 mg and complete STAT6 degradation in both blood and skin at all multiple ascending doses equal to or greater than 50 mg. KT-621 showed a safety profile similar to placebo, with no serious adverse events reported. The trial's results indicate potential for treating IL-4/IL-13-driven allergic diseases. Kymera plans to begin two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-132760), on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}